08223 ZYY
- 1.670
- +0.070+4.38%
ZYY News
ZYY announced that Li Xinpei has been appointed as a non-executive Director.
ZYY (08223) announced that Li Xinpei has been appointed as the company's non-executive Director, effective from December 24, 2024.
Zyy (08223) terminates the rights issue and underwriting agreement.
zyy (08223) announced that, following the signing of the underwriting agreement, the share price experienced a significant decline - 202...
zyy (08223) intends to acquire Hongyang Xintian (Shenzhen) Technology Co., Ltd.
zyy (08223) issued an announcement that on September 27, 2024, the company (buyer) and Shenzhen Hongyang Xintian Chan...
ZYY: INTERIM REPORT 2024
ZYY: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
Zyy (08223) plans to issue new shares at a discount of approximately 66.44% based on the "5 for 3" ratio, raising a maximum of approximately HKD 86 million.
Zyy (08223) announced that the company plans to issue up to 86 million shares at a ratio of 5 to 3 to raise approximately...
Zyy (08223.HK) received an off-market shareholding of 15 million ordinary shares by Tian Zhiwei, worth approximately HKD 19.8 million.
On June 21st, according to documents disclosed by the Hong Kong Stock Exchange on June 21st, Tian Zhiwei increased his shareholding of ZYY (08223.HK) by purchasing 15 million ordinary shares with an average price of HKD 1.32 per share on June 5th, with a total value of approximately HKD 19.8 million. After the shareholding increase, Tian Zhiwei's latest shareholding amount is 15 million shares, and the warehouse ratio has increased from 0.00% to 3.48%. Source of the image: The Stock Exchange of Hong Kong Equity Disclosure. What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) must disclose their shareholding in listed companies. Listed companies.
Zyy (08223.HK): Tian Zhiwei replaces Huang Guoxin as the company's executive director.
On June 19th, GeLongHui reported that zyy (08223.HK) announced that Huang Guoxin had resigned from the position of executive director of the company to devote more time to other business activities under his responsibility, effective June 19, 2024. However, Huang Guoxin will continue to serve the group as authorized representative, joint finance director, joint company secretary, and director of some of our subsidiaries in Hong Kong. On the same day, it was announced that Tian Zhiwei was appointed as an executive director and a member of the remuneration committee of the company, effective June 19, 2024.
ZYY: 2023 ANNUAL REPORT
Ziyuan Yuan (08223) announced annual results. Profit attributable to shareholders of 145.63 million yuan decreased by 7.9% year-on-year
Ziyuanyuan (08223) announced the results for the year ended December 31, 2023. The group obtained total revenue, people...
ZYY: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2023
Ziyuanyuan (08223) plans to discount approximately 19.23% and issue 30 million subscription shares to raise about HK$43.5 million net
According to the Zhitong Finance App, Ziyuan (08223) announced that on December 29, 2023, the company plans to issue 15 million subscription shares to Yu Jianping and Zheng Zhihong respectively. The subscription price for each subscribed share is HK$1.47, a discount of about 19.23% from the closing price of HK$1.82 per share. Net funding of approximately HK$43.5 million is intended to be used for general working capital to develop the Group's financial leasing business and medical device and consumables trading business. On the same day, that is, the final end date of the placement agreement, the prerequisites for the placement agreement have not been met, and the proposed transactions under the placement agreement have expired and been terminated
Zi Yuanyuan (08223) plans to discount approximately 13.28%, place up to 40 million shares, place up to 40 million shares, net raise about HK$42.7 million
Zi Yuanyuan (08223) issued an announcement. On December 12, 2023, the company signed a placement agreement with the placement agent...
Zi Yuanyuan (08223.HK) plans to further develop medical device and consumables trading business
Gelonghui November 24 | Zi Yuanyuan (08223.HK) announced that on November 24, 2023, the company (“buyer”) signed a memorandum of understanding with He Chao, Shenzhen Yunrui Investment Limited Partnership (Limited Partnership) and Shenzhen Borui Cloud Investment Partnership (“Seller”). According to the MOU, the buyer intended to buy and the seller intended to sell shares of Shenzhen Chuangda Yunrui Intelligent Technology Co., Ltd. (“Target Company”) and the buyer intended to inject capital into the target company. After the shares to be sold and capital injections are completed, the Group intends to own 51% of the target company's shares. The target company is a limited company established in China
ZYY: THIRD QUARTERLY REPORT 2023
ZYY: THIRD QUARTERLY RESULTS ANNOUNCEMENTFOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
Zi Yuanyuan (08223.HK) plans to buy Guangdong Dejiang Medical Products Co., Ltd. to develop medical device and consumables trading business
Gelonghui, October 27, Ziyuanyuan (08223.HK) announced that on October 27, 2023, the Company (“Buyer”) signed a Memorandum of Understanding with Hu Yang and Shenzhen Dejiang Investment Co., Ltd. (“Seller”). According to the MOU, the buyer intended to buy and the seller intended to sell shares in Guangdong Dejiang Medical Products Co., Ltd. (“Target Company”). The target company is a limited company established in China, founded in 2017, dedicated to R&D, manufacturing and sales of medical physiotherapy equipment. The founding team of the target company comes from well-known companies in the industry and has many years of work experience in the medical device industry
ZYY: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2022
ZYY: INTERIM REPORT 2023
Ziyuan Yuan (08223.HK)'s interim earnings increased 23.3% to 176 million yuan
On August 11, GLONGHUI | Ziyuan (08223.HK) announced that in the six months ending June 30, 2023, the Group's revenue increased by about 23.3% to about RMB 175.6 million. The total profit and overall revenue attributable to company owners during this period was approximately RMB 6.1 million and RMB 8.1 million, respectively. The decrease in total profit and overall revenue attributable to company owners during this period was mainly due to a decrease in revenue and other net income and loss from the same period in 2022 (i) financial leasing services and maternal and child confinement services; and (ii) increased financing costs, which offset (i) medical devices
No Data